08:31pm Tuesday 23 October 2018

Hunting for “Hot Spots” for Chromosome Reshuffling

Researchers at Children’s Hospital Boston and the Immune Disease Institute (IDI) have created a method for mapping “hot spots” in the genome where chromosomes are most likely to break and recombine, knowledge that help define the rules that govern when and where breaks occur. An understanding of these rules could change the way scientists think about aspects of cancer genomics and also help guide ongoing efforts to develop gene therapy-based treatments for a variety of conditions.

The research team was led by Frederick Alt, the Charles A. Janeway Professor of Pediatrics at Harvard Medical School and director of the IDI and the Program in Cellular and Molecular Medicine at Children’s Hospital Boston. The findings were reported in the September 30 issue of Cell.

In many cancers, whole chromosomes get rearranged or recombined, physically breaking and swapping sections with other chromosomes. These rearrangements, called translocations, connect portions of two genes together to create new “fusion” genes that sometimes combine the functions of the original pair to create a cancer gene.

“People have been characterizing translocations for the last 50 years or so,” said Alt, who is also a Howard Hughes Medical Institute investigator, “but we haven’t understood the mechanisms that form them. We know what happened, but not how it happened.

“This study,” he continued, “helps define what those mechanisms are.”

To better understand the rules that govern where in the genome breaks occur and where a broken piece of a chromosome will land, Alt and his colleagues developed a method for mapping what they call the “translocatome” – the total genome-wide complement of rearrangements for a particular chromosome break. The method, called high-throughput genome-wide translocation sequencing (HTGTS), is based on the action of DNA-cutting enzymes such as I-SceI, a general type of enzyme that is also under scrutiny as a possible gene therapy tool and which Alt’s team used in the current study.

The team found that the broken chromosome segments tend to fuse near the beginnings of genes, at locations called transcription start sites. “The frequency at which translocations occur at transcription start sites is extremely high,” Alt explained, “implying that something about the transcription process itself might encourage chromosome breaks.”

In addition, they have also found that broken chromosomes often rearrange within themselves, as opposed to sharing pieces across different chromosomes. “We’re still in the process of defining what all the translocation rules are,” Alt noted, “but we think that because chromosomes tend to fold into balls, broken ends within a given chromosome tend to be physically closer to each other than to breaks on other chromosomes.”

This greater understanding of where and the rules by which translocations occur could lead to a new way of thinking about how particular genes and translocations contribute to cancer. For instance, HTGTS could help scientists figure out which  oncogenes might contribute to different tumors by showing which have a high potential for containing translocation sites in tumor progenitors.

The method could help also cancer genome researchers determine which translocations in a particular tumor actually play a role in the tumor’s growth and survival and which are, in essence, innocent bystanders.

“Childhood cancers, from leukemias and lymphomas to neuronal tumors, all have an inherent genomic instability that manifests itself in translocations,” said Alt. “But while translocations come up very frequently across the cancer genome, it’s the ones that the cells select for that are important. Our work could help concentrate efforts to understand cancer translocations on those that are related to tumor initiation and which could have some therapeutic value.”

Alt’s team also found that the I-SceI enzyme they used to create chromosome breaks could cut DNA at  as surprising number of previously unrecognized locations across the genome, information that could impact the enzyme’s utility as a tool for gene therapy. “We think that HTGTS could help the gene therapy community better understand the full activity of the enzymes they are considering and avoid possible off-target effects,” Alt said.

The study was supported by the National Cancer Institute, the National Institute of Allergy and Infectious Disease, the Howard Hughes Medical Institute, the Leukemia and Lymphoma Society, and the V Foundation.

Adapted from a Children’s Hospital Boston news release

Children’s Hospital Boston is an affiliated teaching hospital of Harvard Medical School.

Share on:

MORE FROM Genetics and Birth Defects

Health news